Pacira reports preliminary 2025 revenue of $726.4M; EXPAREL sales record high with 7% volume growth

Pacira BioSciences, Inc.

2025-FY EPS reported $0.16 revenue$726,411,000

Total revenue $726.4M vs $701.0M in FY2024, up 3.6%.
Q4 EXPAREL net sales $155.8M (record) vs $147.7M in Q4 2024, 7% volume growth.
Full-year EXPAREL net sales $575.1M vs $549.0M (+4.8%); ZILRETTA flat at $116.6M.
Repurchased 2.0M shares for $50.0M in Q4; $150M remains under current authorization.
Preliminary unaudited; full Q4/fiscal 2025 results and guidance expected later in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.